decitabine + NY-ESO-1 peptide vaccine + pegylated liposomal doxorubicin hydrochloride + sargramostim + incomplete Freund's adjuvant
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Fallopian Tube Cancer
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Trial Timeline
Apr 1, 2009 → Jun 1, 2013
NCT ID
NCT01673217About decitabine + NY-ESO-1 peptide vaccine + pegylated liposomal doxorubicin hydrochloride + sargramostim + incomplete Freund's adjuvant
decitabine + NY-ESO-1 peptide vaccine + pegylated liposomal doxorubicin hydrochloride + sargramostim + incomplete Freund's adjuvant is a phase 1 stage product being developed by Eisai for Recurrent Fallopian Tube Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01673217. Target conditions include Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01673217 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Fallopian Tube Cancer